914462-92-3 Usage
Description
Rolapitant hydrochloride hydrate, originally discovered by Schering-Plough and later developed by TESARO, Inc., is a hydrate that is the monohydrate form of rolapitant hydrochloride. It is a highly selective NK-1 receptor antagonist, exhibiting >1000-fold selectivity for NK-1 over human NK-2 and NK-3 receptors in vitro. Rolapitant shows no inhibition of CYP3A4, is an orally active agent with a relatively long half-life (180 h), and was approved by the FDA in September 2015 for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in combination with other antiemetic agents.
Uses
Used in Pharmaceutical Industry:
Rolapitant hydrochloride is used as a raw material for pharmaceutical formulations for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is used in combination with other antiemetic agents, such as granisetron and dexamethasone, to provide a significant improvement in complete response compared to treatments without rolapitant.
Synthesis
Rolapitant features a fascinating molecular architecture
consisting of two tetrasubstituted stereogenic carbon centers
situated at the 2- and 5-carbons within a central piperidine ring and a spirocyclic array residing at the 5-position and a phenyl
ring and ethereal linkage branching from the 2-position. The overall synthetic strategy to secure rolapitant
hydrochloride hydrate relies upon the union of two advanced
chiral building blocks that contain functional groups capable of
securing the central piperidine ring. These two key
intermediates, pyroglutamate derivative 93 and allylic amine
94, each bear one of the essential stereocenters embedded
within the structure of the active pharmaceutical ingredient.
The first of these advanced intermediates, amidoaldehyde 93, is
generated directly by base-mediated decomposition of
pyroglutamic aminal 92. Subjection of 92 to triethylamine in
EtOH/H2O at ambient temperatures led to generation of chiral
allyl aldehyde 93, which was not isolated but condensed
immediately with amine 94 in the presence of
refluxing toluene to provide divinyl imine 95, which underwent
immediate reduction using NaBH(OAc)3 in AcOH/toluene to
furnish the free amine. The free amine was converted to the
corresponding tosylate monohydrate salt and triturated,
providing 96 as a white crystalline powder after subjection to
TsOH·H2O in i-PrOH/H2O. Divinyl amine 96 could then be
reacted with a solution of TsOH in toluene, distilled, and
directly combined with a toluene solution of Hoveyda-Grubbs
second-generation catalyst (HG-II) under heating conditions,
leading to the desired ring-closing metathesis product 97 as the
HCl salt (85% yield over two steps) after filtration, distillation,
and workup with 12N HCl. Washing of a toluene solution of 97
with aqueous NaOH and subsequent treatment of the resulting
organic solution with H2, wet Pd/C, and additional granular
activated carbon (Nuchar Aquaguard) led to the fully reduced
piperidine product in high yield (95%). Rolapitant hydrochloride
hydrate XIII was accessed thereafter by precipitation
from a solution of EtOH/i-PrOH/H2O/HCl, providing the
product as a white solid (91% yield).
Check Digit Verification of cas no
The CAS Registry Mumber 914462-92-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,4,4,6 and 2 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 914462-92:
(8*9)+(7*1)+(6*4)+(5*4)+(4*6)+(3*2)+(2*9)+(1*2)=173
173 % 10 = 3
So 914462-92-3 is a valid CAS Registry Number.
914462-92-3Relevant articles and documents
Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
-
Page/Page column 8, (2008/06/13)
Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.
